+1-786-628-7980
Sign Up/Sign In 
Atmofizer Technologies Inc. further to its news release of January 3, 2023, effective at the opening of trading on January 12, 2023 (the “Effective Date“) the common shares of the Company (the “Common Shares“) will commence trading on the Canadian Securities Exchange on a consolidated basis, with one (1) post-consolidated Common Share outstanding for every twenty (20) pre-consolidated Common Shares (the “Consolidation“).
As a result of the Consolidation, on the Effective Date, a total of approximately 6,687,390 Common Shares will be issued and outstanding, subject to adjustments for rounding, with approximately 489,207 Common Shares reserved for issuance. No fractional Common Shares will be issued, and any post-Consolidation fraction of a Common Share will be rounded to the nearest whole number of Common Shares. The name of the Company has not been changed, and the trading symbol remains as “ATMO”. A new CUSIP number has been issued for the post-Consolidation Common Shares, being 04952E208.
The exercise or conversion price and the number of Common Shares issuable under any of the Company’s outstanding convertible instruments will be proportionately adjusted upon the effectiveness of the Consolidation.
Shareholders of record as of the Effective Date who hold Common Shares represented by a physical certificate or DRS statement will receive a letter of transmittal from the transfer agent for the Company, Odyssey Trust Company, with instructions on how to exchange their existing certificates or DRS statements for certificates or DRS statements representing Common Shares on a post-Consolidation basis.
About Atmofizer Technologies Inc.
Atmofizer’s consumer and industrial solutions are based on its patent-protected and patent pending technology for ultrafine particle agglomeration and neutralization. This capability creates a revolutionary and more efficient method for addressing the wide range of dangerous nano-scale particles, viruses and bacteria that are too small to be effectively managed by conventional HEPA filters and ultraviolet lights. Atmofizer plans to disrupt the air treatment industry by improving air safety and purification efficiency while lowering customers’ operational costs.
Atmofizing air refers to the process of using ultrasonic acoustic waves to agglomerate (cluster together) small particles into a larger target that is then radiated by ultraviolet light to neutralize their harmful properties, making the air you breath less hazardous to your health. Using units that atmofize air in tandem with high efficiency particulate air (“HEPA“) filters can make the HEPA filters work more efficiently, enable the use of a less-powerful filter and result in a cleaner and longer-lasting filter that reduces operating costs and is less of a health hazard to clean or replace.
Atmofizer is patent-pending and patent-protected sole source of technology to atmofize air and is applying its proprietary technology in consumer and industrial air purification products currently manufactured under the Atmofizer brand, as well as in retail and commercial devices produced by other companies that integrate Atmofizer technology into their own products under license. Atmofizer’s owned and licensed product lines include wearable, portable and mobile use for personal air treatment, as well as larger systems to handle higher air volumes for commercial, industrial, institutional and residential applications.
